Enpatoran showed significant dose-dependent reduction in cutaneous lupus disease activity in phase 2 WILLOW trial
Baseline CRP levels were associated with greater treatment retention for TNF inhibitors but not IL-17 inhibitors in axial spondyloarthritis
Dapagliflozin reduces residual proteinuria in patients with inactive lupus nephritis, randomized crossover trial finds
